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Background/Aims: Helicobacter pylori eradication rates 
are decreasing because of increases in clarithromycin resis-
tance. Thus, finding an easy and accurate method of detect-
ing clarithromycin resistance is important. Methods: We 
evaluated 70 H. pylori isolates from Korean patients. Dual-
labeled peptide nucleic acid (PNA) probes were designed to 
detect resistance associated with point mutations in 23S ri-
bosomal ribonucleic acid gene domain V (A2142G, A2143G, 
and T2182C). Data were analyzed by probe-based fluores-
cence melting curve analysis based on probe-target dissocia-
tion temperatures and compared with Sanger sequencing. 
Results: Among 70 H. pylori isolates, 0, 16, and 58 isolates 
contained A2142G, A2143G, and T2182C mutations, re-
spectively. PNA probe-based analysis exhibited 100.0% posi-
tive predictive values for A2142G and A2143G and a 98.3% 
positive predictive value for T2182C. PNA probe-based 
analysis results correlated with 98.6% of Sanger sequencing 
results (κ-value=0.990; standard error, 0.010). Conclusions: 
H. pylori clarithromycin resistance can be easily and accu-
rately assessed by dual-labeled PNA probe-based melting 
curve analysis if probes are used based on the appropriate 
resistance-related mutations. This method is fast, simple, 
accurate, and adaptable for clinical samples. It may help 
clinicians choose a precise eradication regimen. (Gut Liver 
2018;12:641-647)
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INTRODUCTION
Helicobacter pylori infection is involved in the pathogenesis 
of chronic gastritis, peptic ulcer disease, and mucosa-associated 
lymphoid tissue lymphoma and is a major risk factor for the 
development of gastric cancer.1 The rate of H. pylori infection 
is higher in Korea than in other countries.2 Traditionally, triple 
therapy including a proton pump inhibitor, amoxicillin, and 
clarithromycin has been recommended as the primary regimen 
for H. pylori eradication.3,4 However, clarithromycin resistance 
is prevalent and exceeds more than 20% in Korea.5 Therefore, 
increased resistance to clarithromycin has become the most im-
portant factor of treatment failure. In recent years, eradication 
rates with first-line therapy in South Korea have ranged from 
74.6% to 75.8%.6-8 Clarithromycin resistance is due to point mu-
tations in the peptidyl transferase encoding region in domain V 
of the H. pylori 23S ribosomal ribonucleic acid (rRNA) gene.9,10
Techniques to evaluate clarithromycin resistance can be 
divided into two categories: standard susceptibility tests and 
molecular methods.11-14 However, phenotypical tests such as 
the agar dilution method and Epsilometer (E)-test require com-
plicated conditions for H. pylori growth and serial subcultiva-
tions for several days to determine clarithromycin resistance. 
Furthermore, the agar dilution method and E-test fail to give 
any information about point mutations.15-17 Molecular methods 
such as polymerase chain reaction (PCR), real-time PCR, and 
fluorescence in situ hybridization with deoxyribonucleic acid 
(DNA) probes have been developed to overcome these short-
comings.9,13,18,19
Peptide nucleic acid (PNA) molecules are synthetic DNA mim-
ics, with a negatively-charged sugar-phosphate backbone that 
confers high affinity for DNA or RNA complementary sequenc-
es.20,21 PNA molecules are stable at higher melting temperatures 
and more resistant to nucleases and proteases than DNA mol-
ecules.21 PNA probes are also usually smaller (13–18 bp) than 
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DNA probes (≥18 bp); therefore, they penetrate the bacterial cell 
wall more easily.21,22
In this study, we developed and validated a new genotypic 
method to detect clarithromycin resistance in H. pylori, which 
involved probe-based fluorescence melting curve analysis (Sea-
Sun Biomaterials, Daejeon, Korea) using a set of PNA probes. 
Sanger sequencing was used as the reference method. 
MATERIALS AND METHODS
1. Study settings 
We used 70 H. pylori strains from clinical isolates consecu-
tively which were collected from patients who underwent 
gastric biopsy at Gangnam Severance Hospital, Seoul, Korea, 
between March 2015 and February 2017. We performed PNA 
probe-based fluorescence melting curve analysis compared with 
the standard susceptibility culturing test (E-test; BioMerieux SA, 
Marcy I’Etoile, France) and PCR sequencing to assess resistance 
status of 70 H. pylori strains.
2. Isolation of Helicobacter pylori strains and growth condi-
tions
One antral and one corporal biopsy specimen were placed in 
a transport medium. The gastric tissue specimens were seeded 
in egg yolk emulsion (EYE) agar plates (Yuhan LabTech, Seoul, 
Korea). EYE agar contained Columbia agar 43.82 μg/mL, EYE 
112.36 μL/mL, IsoVitaleX 11.23 μL/mL, and 2,3,5-triphenyltet-
razolium chloride 45.0 μg/mL (for colony staining). The plates 
were subsequently stored in a multigas incubator (microaero-
philic atmosphere: 10% carbon dioxide, 5% oxygen, and 85% 
nitrogen at 37°C) for 3 to 7 days. If H. pylori was not isolated 
after 7 days of incubation, the plates were incubated for 3 more 
days. Isolation of H. pylori was identified on the basis of colony 
morphology and confirmed by matrix-assisted laser desorption/
ionization-time-of-fight mass spectrometry (MALDI-TOF) using 
the Microflex LT system (Bruker Daltonics, Bremen, Germany), 
and the measured profiles were compared to a database with 
MALDI Biotyper 3.1 software (Bruker Daltonics). The colonies 
were re-identified by subculture analysis. In our institution, 
isolation of H. pylori is routinely performed from gastric biopsy 
specimens using the above methodology. In the present study, 
we used isolates of H. pylori that had been in storage.
3. Design of peptide nucleic acid oligonucleotide probes for 
the detection of clarithromycin resistance
PNA probes were designed by adapting existing DNA probes 
targeting three point mutations (A2142G, A2143G, and T2182C) 
of 23S rRNA in H. pylori. The three point mutations were 
chosen based on prior reports. 23S rRNA point mutations typi-
cally involve A2142G or A2143G; in particular, the A2143G 
mutation has been previously identified in approximately 70% 
to 90% of patients with clarithromycin-resistant H. pylori.23,24 
T2182C has also been regarded as an important point mutation 
in clarithromycin-resistant isolates.24 We used the U-TOP™ HPy 
ClaR Detection Kit (SeaSun Biomaterials) to construct the PNA 
probes. 
4. Validation of the real-time PCR-based MeltingArray anal-
ysis
Using the three PNA probes for probe-based fluorescence 
melting curve analysis (SeaSun Biomaterials), real-time PCR 
was performed with the CFX96 Real-Time PCR Detection system 
(Bio-Rad, Hercules, CA, USA), according to the manufacturer’s 
manual. Real-time PCR reactions were performed in 20-μL reac-
tion mixtures containing 10 μL ×2 qPCR PreMix (SeaSun Bio-
materials), 5 μL primer and detection PNA probe mixture, and 
3 μL DNA template (15 ng/μL). The reaction conditions for am-
plification and melting point analysis were 95°C for 10 minutes; 
42 cycles of 95°C for 30 seconds, 58°C for 45 seconds, and 72°C 
for 45 seconds; followed by melting point analysis. Melting 
point analysis was performed using a denaturation step of 95°C 
for 5 minutes; 1-minute hybridization steps of 75°C, 55°C, and 
45°C; and a stepwise temperature increase from 20°C to 85°C at 
1°C per step, with a 5-second interval between each step. The 
data were analyzed using Bio-Rad CFX manager v1.6 software 
(Bio-Rad). Mutations were distinguished by the fluorescence sig-
nal of detection probes and corresponding melting temperatures 
(Tm).
5. Sanger sequencing 
Sanger sequencing was performed as follows. A total of five 
sets of primers were used to amplify genomic DNA (gDNA) re-
gions containing the mutations. PCR was performed using 20-
μL reaction mixtures containing 3 μL purified gDNA (15 ng/μL), 
10 μL ×2 qPCR PreMix (SeaSun Biomaterials), and 0.5 μL each 
of a forward and reverse primer (10 mM). And, thermocycling 
was done using 40 cycles at 95°C for 30 seconds, 58°C for 45 
seconds, and 72°C for 45 seconds, with a final elongation step 
at 72°C for 5 minutes. The PCR products were electrophoresed 
on a 2% agarose gel and showed with ethidium bromide stain-
ing under ultraviolet light to check their sizes and evaluate their 
quantities. PCR products were sequenced using the ABI BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 
Waltham, MA, USA). Sequencing reaction products were elec-
trophoresed on the ABI 3500XL genetic analyzer (Applied Bio-
systems). Sequence data were analyzed using the ABI 3500XL 
DNA Analyzer (Applied Biosystems). All gDNA samples were 
tested individually with each of the eight sets of primers in both 
directions.
6. Antimicrobial susceptibility test
The in vitro minimum inhibitory concentration (MIC) of clar-
ithromycin against the H. pylori clinical isolates was evaluated 
two times using the E-test. The MIC was determined in accor-
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dance with the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) recommendations, with the clinical 
breakpoint for clarithromycin defined as >0.5 mg/L.25 The stan-
dard strain, H. pylori ATCC 43504 (NCTC 11637, Australia), was 
used as a quality control organism.
7. Statistical analysis
PNA probe-based fluorescence melting curve analysis was 
compared with Sanger sequencing to assess resistance status. 
We calculated the positive predictive value (PPV), negative 
predictive value (NPV), and corresponding 95% confidence 
intervals of PNA probe-based fluorescence melting curve 
analysis using Sanger sequencing results as the reference. To 
assess the agreement between PNA probe-based fluorescence 
melting curve analysis and Sanger sequencing, we calculated 
the κ-value. All statistical analyses were conducted using SPSS 
software version 20.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Among 70 H. pylori strains, 22 strains (31.4%) were clar-
ithromycin resistant and 48 strains (68.6%) were clarithromycin 
Table 1. Minimum Inhibitory Concentrations of Clarithromycin for 70 Helicobacter pylori Strains
Strain no. MIC, mg/L Strain no. MIC, mg/L Strain no. MIC, mg/L
H-1 0.032 H-34 0.032 H-67 0.016
H-2 0.032 H-35 0.094 H-68 0.016
H-3 0.064 H-36 0.064 H-69 256*
H-4 0.047 H-37 0.047 H-70 0.047
H-5 0.016 H-38 0.016 H-71 0.064
H-6 192* H-39 0.064 H-72 0.094
H-7 256* H-40 SF H-73 24*
H-8 256* H-41 0.064 H-74 256*
H-9 0.064 H-42 SF H-75 128*
H-10 0.064 H-43 0.016
H-11 0.125 H-44 0.064
H-12 0.016 H-45 256*
H-13 256* H-46 0.032
H-14 SF H-47 SF
H-15 0.19 H-48 48*
H-16 0.047 H-49 0.125
H-17 24* H-50 32*
H-18 0.032 H-51 0.016
H-19 0.023 H-52 0.016
H-20 0.016 H-53 32*
H-21 SF H-54 0.032
H-22 0.023 H-55 64*
H-23 3* H-56 0.023
H-24 48* H-57 0.023
H-25 0.047 H-58 64*
H-26 0.094 H-59 0.023
H-27 0.023 H-60 0.023
H-28 0.094 H-61 0.064
H-29 0.094 H-62 0.032
H-30 256* H-63 0.016
H-31 256* H-64 16*
H-32 0.016 H-65 32*
H-33 256* H-66 0.064
MIC, minimum inhibitory concentrations; H, H. pylori strain; SF, subculture failure. 
*Resistant strains determined by the European Committee on Antimicrobial Susceptibility Testing recommendations.
644  Gut and Liver, Vol. 12, No. 6, November 2018
susceptible by E-test (Table 1). Among 22 clarithromycin resis-
tant isolates, the A2143G mutation was observed in 16 (72.7%) 
isolates and the A2142G mutation was not observed in any 
isolate. We also conducted PNA probe-based fluorescence melt-
ing curve analysis and compared the results with those obtained 
using Sanger sequencing. Fig. 1 shows representative melting 
peaks for each mutation, as well as wild-type sequences. The 
PNA probe-based fluorescence melting curve analysis showed 
distinct melting curves specific to each allele, with Tm values for 
each diagnostic melting peak detected exactly as predicted.
Table 2 summarizes the results obtained by the two meth-
ods (Sanger sequencing and PNA probe-based methods). The 
κ-value between PNA probe-based fluorescence melting curve 
analysis and Sanger sequencing was 0.990 (standard error, 
0.010), indicating that PNA probe-based fluorescence melting 
curve analysis agreed well with Sanger sequencing. When com-
pared with Sanger sequencing, the PPV and NPV of PNA probe-
based fluorescence melting curve analysis were both 100.0% 
for the A2142G mutation, as well as the A2143G mutation. 
The PPV was 98.3% and NPV was 100% for the T2182C muta-
tion. One isolate with a T2190C mutation was recognized as a 
T2182C mutation in the PNA probe-based fluorescence melting 
curve analysis. This is likely because the melting temperatures 
of T2182C and T2190C overlapped. Therefore, the concordance 
between PNA probe-based fluorescence melting curve analysis 
and Sanger sequencing in our study was 98.6% (69/70). 
The A2142G mutation was not observed in any of the 70 H. 
pylori isolates. However, the T2182C mutation was found in 58 
isolates (82.9%), suggesting that this mutation was not associ-
ated with clarithromycin resistance (Supplementary Table 1). 
DISCUSSION 
New techniques using a rapid, simple, and accurate method 
to detect clarithromycin resistance have become an emerging is-
sue because of increasing eradication failure of H. pylori. In this 
study, we evaluated a new diagnostic method using PNA probe-
based fluorescence melting curve analysis. This method has 
several advantages. Firstly, this method requires only a conven-
tional real-time PCR machine, and the procedure is performed 
in a single step within a closed well. Therefore, sample contami-
nation and loss are much lower than with other methods, and 
the reaction and analysis procedures are much faster. Accord-
ingly, this method can provide results promptly and accurately. 
The commercialized DPO-PCR (Seeplex® ClaR-H. pylori ACE 
Detection, Seegene Institute of Life Science, Seoul, Korea) is per-
formed in two steps. DPO-PCR is a multiplex PCR and analyzed 
using a semi-automated system (i.e., Screen tape®). Therefore, 
PNA probe-based fluorescence melting curve analysis is faster 
and simple. In addition, PNA probes are simple to design and 
modify. Therefore, we can easily modify the probes and prim-
ers to change the target mutations from relatively nonspecific 
mutations to mutations strongly associated with clarithromycin 
resistance. Furthermore, PNA probe-based fluorescence melt-
ing curve analysis can detect up to four mutations in a single 
well. Probe-based fluorescence melting curve analysis is also a 
powerful tool to detect mutations.8 PNA probes hybridize with 
Table 2. Comparison of Mutation-Detection Results Obtained with the 
PNA-Probe-Based Melting Curve Analysis and Sanger Sequencing
Sanger  
sequencing
PNA melting curve analysis kit
A2142G A2143G T2182C
+ – + – + –
A2142G + 0  0
– 0 70
A2143G + 16  0
–  0 54
T2182C + 58  0
–  1 11
PNA, peptide nucleic acid.
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Fig. 1. Representative melting peaks of (A) A2142G, (B) A2143G, and (C) T2182C mutations. 
WT, wild type; RFU, relative fluorescence unit.
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their complementary target DNA sequences,26 and PNA–DNA 
hybridization is more sensitive to base mismatches than DNA–
DNA hybridization. Because PNA probe-based fluorescence 
melting curve analysis is based on the temperature at which the 
probe-target hybridization dissociates,27 the results are much 
easier to interpret than those of Sanger sequencing. However, in 
this study, PNA melting curve analysis was performed on DNA 
isolated from cultured H. pylori, not on gastric biopsy specimen. 
Therefore, the performance of PNA melting curve analysis on 
gastric biopsy specimens need to be verified.
In this study, we chose three specific mutations: A2142G, 
A2143G, and T2182C. However, the T2182C mutation, which 
was previously regarded as an important point mutation in 
clarithromycin resistance,24,28 was detected in 58 of 70 isolates 
(82.9%). This result indicates that T2182C is a nonspecific muta-
tion, which does not play an important role in clarithromycin 
resistance. As we can change the target mutation panel by add-
ing or removing PNA probes and primers, we can easily replace 
the target mutation of T2182C to up to four different resistant 
target mutations. 
This is the first study to report on using the MeltingArray as-
say based on PNA probes to assess clarithromycin resistance of H. 
pylori. The performance of PNA melting curve analysis showed 
almost 100% correlation with Sanger sequencing. Clinical ap-
plication of our method is easy, and it should help clinicians 
choose appropriate treatment strategies according to the pres-
ence or absence of clarithromycin resistance. Currently, guide-
lines for treating H. pylori infection in Korea recommend an 
algorithm of H. pylori eradication according to clarithromycin 
resistance status.2 Detection of clarithromycin resistance before 
treatment is thereby important for selecting the appropriate 
eradication regimen because assessing clarithromycin resistance 
is the first step in treating H. pylori. Therefore, rapid, easy, and 
accurate methods for detecting clarithromycin resistance are 
necessary, and the PNA probe-based fluorescence melting curve 
analysis is a good candidate method. 
Clarithromycin resistance of H. pylori is well known. Point 
mutations in the 23s rRNA gene decrease the affinity between 
ribosomes and clarithromycin so the antibiotic is unable to 
inhibit protein biosynthesis.29 Mutations A2143G, A2142C/G, 
and A2144G are associated with clarithromycin resistance of 
H. pylori in Asia.30-33 In Korea, 23S rRNA gene mutations such 
as A2142G, A2143G, A2144G, T2182C, T2190C, A2223G, and 
C2195T have been reported occasionally in clarithromycin-
resistant H. pylori strains.24,34-36 However, these point mutations 
are less prevalent, indicating that a causal link between this 
gene and clarithromycin resistance has not been definitively 
proven. In this study, among 70 H. pylori strains, 22 (31.4%) 
were clarithromycin resistant and 48 (68.6%) were clarithromy-
cin susceptible, according to the E-test (Supplementary Table 
1). However, among the 22 clarithromycin-resistant isolates 
based on the E-test, the A2143G mutation was present in only 
16 isolates (72.7%), and the A2142G mutation was not observed 
in any isolate. Therefore, the current commercial kit targeting 
A2142G and A2143G cannot detect all clarithromycin-resistant 
strains. However, as mentioned above, probes can be easily 
designed and modified for PNA probe-based fluorescence melt-
ing curve analysis. As we can change the target mutations by 
modifying probes and primers to identify candidate mutations 
associated with clarithromycin resistance, we can easily and 
conveniently apply this kit to clinical practice for detecting H. 
pylori resistance. 
In this study, DNA sequencing was used to detect the mecha-
nism of clarithromycin resistance. C375T, A381C, and G382A 
mutations that have not been previously associated with clar-
ithromycin resistance were detected more frequently in clar-
ithromycin-resistant isolates than in clarithromycin-susceptible 
isolates (Supplementary Table 2). However, the role of these 
three mutations remains unclear.
In the present study, PNA melting curve analysis was per-
formed on DNA isolated from cultured H. pylori. However, 
PNA melting curve analysis can be performed on gastric biopsy 
specimens, as well as culture-based H. pylori isolates. Consider-
ing the higher rate of H. pylori detection by PCR of gastric bi-
opsy specimens compared with cultures,23,37 PNA melting curve 
analysis should likewise be more useful using gastric biopsy 
specimens than cultures because H. pylori is not easily isolated 
from cultures. Therefore, further study will be needed to validate 
the PNA melting curve analysis on gastric biopsy specimen.
In conclusion, although further study in a large population is 
necessary to confirm our results, PNA probe-based fluorescence 
melting curve analysis can be applied to clinical samples and 
may be helpful in choosing the precise H. pylori eradication reg-
imen according to clarithromycin resistance. When more accu-
rate information becomes available regarding resistance-related 
mutations, we will be able to promptly update our PNA probes 
and primers and thereby easily identify most clarithromycin-
resistant strains.
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